凯特疗法

2023年8月8日

阿斯特拉投资50美元波赛达CAR-T细胞疗法作为协议的一部分,阿斯特拉将独家谈判和优先购买权许可P-MUC1C-ALLO1固体肿瘤。波赛达有战略许可协议与罗氏CAR-T细胞疗法,这是价值高达60亿美元。阿斯特拉制药计划投资50美元在波赛达疗法获得独家谈判和优先购买权的权利许可P-MUC1C-ALLO1固体肿瘤。总投资,25美元的一次性付款,另一半是花了买波赛达约8.8%的普通股(大约每八百万股价值3美元)在一个私人配售,按照8月7日的新闻稿。推荐报告的消息导致了高水平的交易活动波赛达的股票和股票价格上涨约32.5%,当市场8月7日开业,相比市场关闭前一个工作日。P-MUC1C-ALLO1是同种异体嵌合抗原受体(汽车)癌症特异性T细胞疗法目标形式的粘蛋白1蛋白质(MUC1-C)。目前在非盲多中心正在调查第一阶段临床试验(NCT05239143)治疗多个epithelial-derived固体肿瘤的迹象。波赛达战略与罗氏公司许可协议,价值60亿美元。协议授予多个CAR-T罗氏专有权细胞疗法针对血液学的条件是波赛达的投资组合的一部分。的母公司是GlobalData制药技术。 Astellas has entered into multiple licensing and development agreements this year including one with Kate Therapeutics for KT430 gene therapy for the treatment of a rare neuromuscular disease, a drug development agreement for the discovery and development of multiple targeted protein degraders with Cullegen , and a research agreement with Veneno Technologies for drug discovery of functional peptides for various indications. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy Share this article